References: Initial antiretroviral for HIV infection adults

  • Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019;393(10167):143-55. https://www.ncbi.nlm.nih.gov/pubmed/30420123
  • Kryst J, Kawalec P, Pilc A. Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2015;10(5):e0124279. https://www.ncbi.nlm.nih.gov/pubmed/25933004/
  • Messiaen P, Wensing AM, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS ONE 2013;8(1):e52562. https://www.ncbi.nlm.nih.gov/pubmed/23341902
  • Radford M, Parks DC, Ferrante S, Punekar Y. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. AIDS 2019;33(11):1739-49. https://www.ncbi.nlm.nih.gov/pubmed/31180906
  • Shu Y, Qiu C, Tu X, Deng Z, Deng Y, Wang H, et al. Efficacy and Safety of Triple versus Dolutegravir-based Dual Therapy in Patients with HIV-1 Infection: A Meta-analysis of Randomized Controlled Trials. AIDS Rev 2021;23(3):133-42. https://www.ncbi.nlm.nih.gov/pubmed/34082439
  • Wang JX, Zhang SM, Li XH, Zhang Y, Xu ZY, Cao B. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. Int J Infect Dis 2016;48:40-5. https://www.ncbi.nlm.nih.gov/pubmed/27155210